Brief: Ryvu Therapeutics Says Company To Receive Development Milestone Of EUR 1 Mln
Dec 30 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* MENARINI GROUP HAS BEEN GRANTED AN EXCLUSIVE LICENSE TO
DEVELOP
SEL24
* AS A RESULT, COMPANY IS DUE A DEVELOPMENT MILESTONE IN
AMOUNT OF
EUR 1.0 MILLION
Source text for Eikon: ID:nEM78CHcka
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project